Cello Health PLC Directorate Change (3775G)

TIDMCLL

RNS Number : 3775G

Cello Health PLC

05 November 2018

5 November 2018

Cello Health plc

("Cello", the "Company", or the "Group")

Directorate Change

Cello Health plc (AIM: CLL), the global healthcare focused advisory group, is pleased to announce the appointment of Chris Jones as Non-Executive Chairman of the Group with immediate effect, following the retirement of Allan Rich from the Board.

Chris Jones has been a Non-Executive Director of Cello since October 2016. He was formerly Global Chairman and CEO of J Walter Thompson Co based in New York, part of WPP Group plc. Amongst other directorships, Chris is also a director of Becton Dickinson & Co, the major US-based multinational medical technology company.

Mark Scott, Chief Executive, commented: "The Board wishes to wholeheartedly thank Allan Rich for his invaluable contribution to Cello over the years from its inception. Chris knows the group and the healthcare industry well and can help guide the Board through the Group's next stage of growth and development."

Enquiries:

 
 Cello Group                       020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Finance Director 
 
 Cenkos Securities                 0207 397 8900 
 Mark Connelly 
  Harry Hargreaves

Appendix

 
 Full name (age) 
 Christopher Ian Montague Jones (63) 
 Current directorships / partnerships: 
 CELLO HEALTH PLC 
  BECTON, DICKINSON AND COMPANY 
  PALMER HARGREAVES HOLDINGS LIMITED 
  THE PEW TRUSTS 
  INTERNATIONAL INSTITUTE FOR STRATEGIC STUDIES 
  17-18 BUCKINGHAM STREET FREEHOLD LIMITED 
  DRAGON ACADEMY HOLDINGS LIMITED 
  BLACKBIRD ACADEMY TRUST 
  RESULTS INTERNATIONAL GROUP LLP 
  DRAGON SCHOOL TRUST LIMITED 
  ST.EDWARD'S SCHOOL 
 Previous directorships / partnerships (in the last 
  five years): 
 6AM (UK) LTD 
  COVENANT HEALTHCARE GROUP LIMITED 
  THE PAVILION CLINIC LTD 
  GRAND UNION COMMUNICATIONS LIMITED 
  EKINO LIMITED 
  FULLSIX MEDIA LIMITED 
  AMIGO MANAGEMENT SERVICES LTD 
  AMIGO LOANS LTD 
  RICHMOND GROUP LIMITED 
  MOTION EQUITY PARTNERS LLP

As at today's date, Mr Jones holds 22,726 ordinary shares in the capital of the Company.

There are no further disclosures to be made pursuant to Schedule 2(g) of the AIM Rules for Companies in respect of Mr Jones' appointment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOALLFVVLLLEIIT

(END) Dow Jones Newswires

November 05, 2018 09:00 ET (14:00 GMT)

Cello Health (LSE:CLL)
Historical Stock Chart
From Jun 2024 to Jul 2024